Novel oral anticoagulants in the treatment of cancer patients Review article

Article Sidebar

PDF


Published: Mar 31, 2014
Keywords:
novel anticoagulants, venous thromboembolism, cancer

Main Article Content

Renata Biernacka
Department of Chemotherapy, Oncology Clinic, Maria Skłodowska-Curie Institute of Oncology, Warsaw
Tomasz Lewandowski
Department of Chemotherapy, Oncology Clinic, Maria Skłodowska-Curie Institute of Oncology, Warsaw
Jolanta Andrzejuk
Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie Institute of Oncology, Warsaw
Marek Szmyd
Department of Chemotherapy, Oncology Clinic, Maria Skłodowska-Curie Institute of Oncology, Warsaw

Abstract

Cancer and its treatment are well-recognized risk factors for venous thromboembolism. The risk of thrombotic complications increases 4–7-fold in cancer patients and coexistence of both pathologies is associated with shorter survival. Incidence of thrombosis depends on the tumour type, antineoplastic and supportive therapy, and patient-related factors such as age, physical activity and comorbidities. Current recommendations of scientific societies indicate a dominant role of low molecular weight heparins in the treatment and prevention of venous thromboembolism in cancer patients. Long duration of the anticoagulant effect, and the subcutaneous administration route of heparins call for a safer therapeutic option, and one that would be more convenient for the patient. New oral anticoagulants: dabigatran, rivaroxaban, and apixaban, are indicated as prevention of venous thromboembolism following an orthopaedic surgery, and as stroke prevention in nonvalvular atrial fibrillation, with rivaroxaban also applied in the treatment of acute deep vein thrombosis and pulmonary embolism. In the trials evaluating the efficacy of novel oral anticoagulants, they have been compared with enoxaparin or vitamin K antagonists. Cancer patients accounted for a small percentage of the trial population, and they were rarely analysed in subgroup analysis. It was only in the phase II ADVOCATE study that the target group were patients receiving chemotherapy. Direct comparison between test drug and low molecular weight heparins was not performed. The currently available study results do not allow us to recommend the new oral anticoagulants for the treatment and prevention of venous thromboembolism associated with cancer.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Biernacka R, Lewandowski T, Andrzejuk J, Szmyd M. Novel oral anticoagulants in the treatment of cancer patients. OncoReview [Internet]. 2014Mar.31 [cited 2024May6];4(1(13):11-7. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/354
Issue
Vol 4 No 1(13) (2014)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Blom JW, Vanderschoot JP, Oostindiër MJ et al. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006; 4(3): 529-535.
2. Timp JF, Braekkan SK, Versteeg HH et al. Epidemiology of cancer-associated venous thrombosis. Blood 2013; 122(10): 1712-23.
3. SØrensen HT, Mellemkjær L, Olsen JH et al. Prognosis of Cancers Associated with Venous Thromboembolism. N Engl J Med 2000; 343: 1846-1850.
4. Khorana AA, Francis CW, Culakova E et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5(3): 632-634.
5. Cronin-Fenton DP, SØndergaard F, Pedersen LA et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer 2010; 103(7): 947-953.
6. Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 2012; 9(7): e1001275.
7. Ahlbrecht J, Dickmann B, Ay C et al. Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2012; 30(31): 3870-3875.
8. Khorana AA, Francis CW, Culakova E et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007; 110(10): 2339-2346.
9. White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003; 90(3): 446-455.
10. Falanga A, Russo L, Verzeroli C. Mechanisms of thrombosis in cancer. Thromb Res 2013; 131(supl 1): S59-62.
11. Zawilska K, Bała M, Błędowski P et al. Polish Guidelines for the prevention and Treatment of Venous Thromboembolism – 2012 Update.
12. Lyman GH, Khorana AA, Kuderer NM et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2013; 31(17): 2189-2204.
13. Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group: Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22(supl. 6): vi85-92.
14. Antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: 1S-e801S.
15. Online: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR.
16. Cohen AT, Spiro TE, Büller HR et al; MAGELLAN Investigators: Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368(6): 513-523.
17. Gómez-Outes A, Suárez-Gea ML, Lecumberri R et al. Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients. Vasc Health Risk Manag 2013; 9: 207-228.
18. Goldhaber SZ, Leizorovicz A, Kakkar AK et al; ADOPT Trial Investigators: Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011; 365(23): 2167-2177.
19. Schulman S, Kearon C, Kakkar AK et al; RE-COVER Study Group: Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361(24): 2342-2352.
20. EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363(26): 2499-510.
21. EINSTEIN-PE Investigators; Büller HR, Prins MH, Lensin AW et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366(14): 1287-97.
22. Agnelli G, Buller HR, Cohen A et al; AMPLIFY Investigators: Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369(9): 799-808.
23. Schulman S, Kearon C, Kakkar AK et al; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators: Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368(8): 709-18.
24. Agnelli G, Buller HR, Cohen A et al; AMPLIFY-EXT Investigators: Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368(8): 699-708.
25. Levine MN, Gu C, Liebman HA et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost 2012; 10(5): 807-14.